Victrelis™ (Boceprevir): The New Hepatitis C Drug
Share
Follow Us
The Editors at Hepatitis Central
May 20, 2011
With the approval of Victrelis™ (boceprevir) for the treatment of those with Hepatitis C, genotype 1, many questions arise. Here we have summarized some of these questions.
by Editors at Hepatitis-Central.com
With the approval of a new treatment option for those with Hepatitis C genotype 1 there is bound to be questions. Based on the information provided by Merck, developer of Victrelis™, we have provided summaries for many of the questions that are being asked. Learning more about this new combination therapy and discussing this information with your healthcare provider are essential.
Simply click on any of the links below for more details:
- What is Victrelis™ (boceprevir)?
- What is the dosage for Victrelis™ (boceprevir)?
- Does the dosage and administration of Victrelis (boceprevir) differ for various people?
- When is Victrelis™ contraindicated?
- What types of adverse reactions were reported when taking Victrelis™?
- What if one has an adverse reaction to the Victrelis™ combination therapy?
- Are there any other warnings one should know regarding Victrelis™ combination therapy?
- At what point would one know the Victrelis™ combination treatment is not working?
- Can those co-infected with HIV and Hepatitis C begin Victrelis™ combination therapy?
- When can I get a prescription for Victrelis™ (boceprevir)?
- How can I get assistance paying for Victrelis™ (boceprevir)? Is Victrelis™ covered by insurance?
